Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Movement Disorders

• Publication date

  2016-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/mds.26754PMID 27548849
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice.

  2016cited by this paper
• Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease

  2016cited by this paper
• Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

  2016influential reference
• Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases

  2016cited by this paper
• Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases—From pathophysiology to clinical practice

  2016cited by this paper
• Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease

  2015cited by this paper
• CSF biomarkers and clinical progression of Parkinson disease

  2015cited by this paper
• Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils.

  2015cited by this paper
• Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.

  2015cited by this paper
• Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

  2015cited by this paper
• Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

  2014cited by this paper
• Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

  2014cited by this paper
• Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

  2014cited by this paper
• Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease

  2014cited by this paper
• Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity

  2014cited by this paper
• Reduced α‐synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity

  2014cited by this paper
• Cerebrospinal fluid biomarkers in Parkinson disease

  2013cited by this paper
• Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

  2013cited by this paper
• Differences in brain activation between tremor- and nontremor-dominant Parkinson disease.

  2012cited by this paper
• α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

  2011cited by this paper
• Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

  2011cited by this paper
• Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias

  2011cited by this paper
• The relation between cognition and motor dysfunction in drug‐naive newly diagnosed patients with Parkinson's disease

  2011cited by this paper
• Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood

  2008cited by this paper
• Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

  2006cited by this paper
• Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease.

  2006cited by this paper
• α-Synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy

  2005cited by this paper
• Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.

  2005cited by this paper
• Soluble oligomers for the diagnosis of neurodegenerative diseases.

  2003cited by this paper
• Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments

  1998cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• Conformations of beta-amyloid in solution.

  1997cited by this paper
• Variable expression of Parkinson's disease

  1990cited by this paper
• DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.

  1989cited by this paper

• Early diagnosis of Parkinson’s disease: biomarker study

  2025cites this paper
• Bioanalytical Considerations for Biomarkers of Parkinson's Disease

  2025cites this paper
• Serum HDL-cholesterol is associated with the clinical-biological profile of early-stage Parkinson's disease patients independently of APOE.

  2025cites this paper
• Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort study

  2025cites this paper
• Quantitative measurements of α-synuclein seeds in CSF inform diagnosis of synucleinopathies

  2025cites this paper
• Phosphorylated α-synuclein in CSF and plasma does not reflect synucleinopathy

  2025cites this paper
• Safety and Feasibility of Serial Lumbar Punctures: Long-term Results from the Parkinson’s Progression Markers Initiative

  2025cites this paper
• Micro- and nanoscale biosensing technologies for early diagnosis of Parkinson’s disease

  2025cites this paper
• Predicting Parkinson’s disease and its progression based on radiomics in T1-weight images and α‑synuclein in cerebrospinal fluid

  2025cites this paper
• Longitudinal Study of Salivary Biomarkers in the Definition of Clinico‐Molecular Progression of Parkinson's Disease

  2025cites this paper
• Utility of Baseline Pathological, Neuroimaging and Clinical Markers for Prognosis in Early Parkinson's Disease.

  2025cites this paper
• Modulating Cerebrospinal Fluid Composition in Neurodegenerative Processes: Modern Drug Delivery and Clearance Strategies

  2025cites this paper
• Microfluidic platform for understanding Parkinson’s disease and α-synuclein conformation

  2025cites this paper
• Serum Oligomeric α-Synuclein and p-tau181 in Progressive Supranuclear Palsy and Parkinson’s Disease

  2024cites this paper
• An immunoassay for the quantification of phosphorylated α-synuclein at serine 129 in human cerebrospinal fluid

  2024influential citation
• Parkinson disease therapy: current strategies and future research priorities

  2024cites this paper
• Longitudinal correlation of cerebrospinal fluid GFAP and the progression of cognition decline in different clinical subtypes of Parkinson's disease

  2024cites this paper
• Research advancement in fluid biomarkers for Parkinson’s disease

  2024cites this paper
• Intracerebroventricular injection of α-synuclein preformed fibrils do not induce motor and olfactory impairment in C57BL/6 mice.

  2024cites this paper
• The Role of α-Synuclein in Etiology of Neurodegenerative Diseases

  2024cites this paper
• Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions

  2024cites this paper
• An update on new-age potential biomarkers for Parkinson's disease.

  2024cites this paper
• Development of a Novel Electrochemiluminescence ELISA for Quantification of α-Synuclein Phosphorylated at Ser129 in Biological Samples

  2023cites this paper
• Fluorescent Peptide-based Probe for the Detection of Alpha-synuclein Aggregates in the Gut

  2023cites this paper
• Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson’s Disease

  2023cites this paper
• How should we be using biomarkers in trials of disease modification in Parkinson’s disease?

  2023cites this paper
• Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative

  2023cites this paper
• Identification of Parkinson's Disease Subtypes from Resting‐State Electroencephalography

  2023cites this paper
• Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?

  2023cites this paper
• Longitudinal hippocampal subfields, CSF biomarkers, and cognition in patients with Parkinson disease

  2023cites this paper
• Parkinson’s disease therapy: what lies ahead?

  2023cites this paper
• Fluid and Biopsy Based Biomarkers in Parkinson’s Disease

  2023cites this paper
• CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment

  2023cites this paper
• Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease

  2023cites this paper
• Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay

  2023cites this paper
• Role of novel endpoints and evaluations of response in Parkinson disease.

  2023cites this paper
• Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool

  2023cites this paper
• Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage

  2023cites this paper
• Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson’s disease

  2023cites this paper
• The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex

  2022cites this paper
• Multi-predictor modeling for predicting early Parkinson’s disease and non-motor symptoms progression

  2022cites this paper
• Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies

  2022cites this paper
• Changes in the cerebrospinal fluid proteome precede and stratify the course of Parkinson's Disease

  2022cites this paper
• Characterization of Parkinson's Disease Subtypes and Related Attributes

  2022cites this paper
• Colony-stimulating factor 1 receptor signaling in the central nervous system and the potential of its pharmacological inhibitors to halt the progression of neurological disorders

  2022cites this paper
• Monogenetic Forms of Parkinson’s Disease – Bridging the Gap Between Genetics and Biomarkers

  2022cites this paper
• Update on CSF Biomarkers in Parkinson’s Disease

  2022influential citation
• Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers

  2022cites this paper
• Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage

  2022cites this paper
• Future Prospects in Parkinson's Disease Diagnosis and Treatment.

  2022cites this paper
• Neurofilament light as a biomarker for motor decline in Parkinson’s disease

  2022cites this paper
• Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson’s Disease: Roads to Biomarker Discovery

  2021cites this paper
• Cerebrospinal α‐Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort

  2021cites this paper
• Temporal trajectory of biofluid markers in Parkinson’s disease

  2021cites this paper
• Disrupted rich-club organization of brain structural networks in Parkinson’s disease

  2021cites this paper
• Synuclein in neurodegeneration.

  2021cites this paper
• Modulation of the Interactions Between α-Synuclein and Lipid Membranes by Post-translational Modifications

  2021cites this paper
• Lewy Body Dementias: A Coin with Two Sides?

  2021cites this paper
• Parkinson's disease: Genetic-driven therapeutic approaches

  2021cites this paper
• Mini Review: Correlations of Cognitive Domains With Cerebrospinal Fluid α-Synuclein Levels in Patients With Parkinson's Disease

  2021cites this paper
• Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders

  2021cites this paper
• A simple-to-use web-based calculator for survival prediction in Parkinson’s disease

  2021cites this paper
• Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients

  2021cites this paper
• Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?

  2021cites this paper
• Investigation of α-synuclein species in plasma exosomes and the oligomeric and phosphorylated α-synuclein as potential peripheral biomarker of Parkinson's Disease.

  2021cites this paper
• Challenges Viewed from Afar

  2020cites this paper
• Systemic Activation of Nrf2 Pathway in Parkinson's Disease

  2020cites this paper
• The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers

  2020cites this paper
• Molecular profiling in Parkinsonian syndromes: CSF biomarkers.

  2020cites this paper
• Advances in modelling alpha-synuclein-induced Parkinson's diseases in rodents: virus-based models versus inoculation of exogenous preformed toxic species.

  2020cites this paper
• New markers in Parkinson's disease.

  2020cites this paper
• CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers

  2020cites this paper
• Clinical and Imaging Markers of Prodromal Parkinson's Disease

  2020cites this paper
• Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction.

  2020cites this paper
• The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease

  2020influential citation
• Development of early diagnosis of Parkinson's disease: Illusion or reality?

  2020cites this paper
• Metabolomics Fingerprint Induced by the Intranigral Inoculation of Exogenous Human Alpha-Synuclein Oligomers in a Rat Model of Parkinson’s Disease

  2020cites this paper
• Brain Fables

  2020cites this paper
• Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers

  2020cites this paper
• CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment.

  2020cites this paper
• Modeling Parkinson’s Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers

  2020cites this paper
• Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinson’s Disease

  2020cites this paper
• The Hypothesis That Refuses to Die

  2020cites this paper
• The Scientific and Lay Narratives

  2020cites this paper
• Preface 2 – Enter Patient

  2020cites this paper
• Disease Subtypes: The Promise and the Fallacy

  2020cites this paper
• Symptomatic vs. Disease-Modifying Therapies

  2020cites this paper
• Disease “Redefinition”: A Tough Pill to Swallow

  2020cites this paper
• Epilogue

  2020cites this paper
• Index

  2020cites this paper
• Lessons from Oncology

  2020cites this paper
• Preface 1 – The Question

  2020cites this paper
• References

  2020cites this paper
• Predictions for the 2020s and Beyond

  2020cites this paper
• The Fault in Our Models

  2020cites this paper
• Biomarkers: The Promise and the Fallacy

  2020cites this paper
• Note Added at Press Time – Reviving LOF

  2020cites this paper
• Our Living Dissonance

  2020cites this paper
• Protein Paradox

  2020cites this paper
• The Shaky Six and the “Second Reality”

  2020cites this paper